Abstract: The invention provides compositions, methods, and kits for the diagnosis or detection of active, latent, or prior infection with human herpesvirus 8 in a subject sample.

Abstract: There is provided an inhibitor that inhibits casein kinase 1? and casein kinase 1?, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1? or casein kinase 1? is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.

Abstract: The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from A. americanum saliva effective in reducing the viability of gram positive, gram negative, or acid-fast bacteria and spirochetes including B. burgdurferi is administered. The inventive protein from A. americanum saliva has utility as a therapeutic for the treatment of an organism infected with bacteria, particularly the spirochete B. burgdorferi.

Abstract: A method of controlling microorganisms such as lactobacilli metabolism in mash in an ethanol production facility includes adding to the mash an effective amount to control such microorganisms of one or more of a substantially water insoluble pristinamycin-type antimicrobial agent, a substantially water insoluble polyether ionophore antimicrobial agent, or both, wherein the term “substantially water insoluble” means the antimicrobial agent has a solubility in pure water at 20° C. of 0.

Abstract: Genome-wide association studies have been used to elucidate genes and/or pathways related to diseases; however, this methodology has yet to be used to understand the phenotype of healthy aging and/or healthspan in humans.

Abstract: The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably P1GF-2 and P1GF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.

Abstract: A microfluidic device comprising a first surface portion and a first sample retaining element, which have differing affinities to a fluid, and a method comprising supplying a sample to such a device. In some embodiments, the differing affinity is a result of plasma, ion embedding, surface charging, chemical, optical, electronic and/or electromagnetic treatment. Also, a microfluidic device comprising at least one microcapillary device having a sample retaining element, at least one surface of which exhibits hydrophobicity, hydrophilicity, electromagnetic force exertion and electrostatic force exertion. Also, a microfluidic device comprising a first element having a hydrophilic pattern comprising at least a first sample retaining element. Also, a method comprising supplying a sample to a channel between a first element and a second element, and inducing in the first element at least one hydrophilic pattern by electrets or by internal or external electrodes to provide a charged surface.

Abstract: Systems and methods for branding medication are provided, including, a first capper system that caps a first medication container with a first cap of a first branding including first identification of a third party supplier of one of the prescription and medication order; a second capper system that caps a second medication container with a second cap of a second branding including second identification of another third party supplier of the one of the prescription and medication order; a transport system that transports the first and second medication containers; and a control system that controls the transport system to transport the first and second medication containers based on customer information, and controls the one of the first capper system and the second capper system to cap the first and second medication containers with one of the first and second caps.

Abstract: This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, and intermediates useful in the preparation of same.

Abstract: The present invention includes methods of treating or preventing malaria by administering an anti-malarial effective amount of 6-substituted uridine derivatives to a subject need thereof. The invention also includes new 6-substituted uridine derivatives for use as therapeutics, in particular to treat malaria.

Abstract: A method of producing volume renderings from magnetic resonance image data in real time with user interactivity. The method comprises collecting raw magnetic resonance image (MRI) data representative of shapes within an image volume; transferring the raw MRI data to a computer; and continuously producing volume renderings from the raw MRI data in real time with respect to the act of collecting raw MRI data representative of shapes within the image volume.

Abstract: The Cellular GPRS system includes a cellular-based Glucometer (CBG) for blood glucose monitoring, a pedometer for exertion measurement, combined with user-entered dietary or other diabetes-relevant information. Data from all inputs is transmitted over a cellular network, using a GPRS or other wireless link. The data is preferably stored in the device prior to being transmitted wirelessly over the cellular airway to a central computer server. The remote computer server will evaluate the data received and respond with a data packet (making recommendations on further glucose measurement, exercise, diet, insulin requirements or other).

Abstract: The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.

Abstract: A scytovirin domain 1 (SD1) polypeptide, a nucleic acid encoding the polypeptide, and related fusion proteins, conjugates, isolated cells, vectors, and antibodies, as well as a method of inhibiting a viral infection using the same.

Abstract: A method of microcalcification detection in a digital mammographic image identifies one or more potential microcalcification sites in the mammographic image according to spot clustering. Each of the one or more potential microcalcification sites is assigned either as a member of a positive candidate set or as a member of a rejected candidate set. Optionally at least one subsequent classifier process that selectively assigns zero or more members of the positive candidate set to the rejected candidate set is executed, according to results from the at least one subsequent classifier process. One or more members of the rejected candidate set are selected as a reclamation candidate set according to results from the initial and any subsequent classifier process. One or more members of the reclamation candidate set are assigned either back to the rejected candidate set or to the positive candidate set according to results from a reclamation classifier process.

Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.

Abstract: A formulation comprising jasmonate for improving cardiac muscle function, particularly by modulating myocardial contractility in a subject is disclosed. Such a formulation may be used to treat a heart or cardiac related disorder.

Abstract: A method for determining whether a human individual is or has been infected with Neisseria gonorrhoeae, is provided. The method detects a Neisseria gonorrhoeae, porA nucleic acid fragment obtained from a biological sample. The method includes subjecting the biological sample to nucleic acid sequence amplification using primers having respective nucleotide sequences according to SEQ ID NO:1 and SEQ ID NO:2, to thereby produce a porA Neisseria gonorrhoeae, amplification product. The amplification product is detected by fluorescence resonance energy transfer using oligonucleotides having respective nucleotide sequences according to SEQ ID NO:3 which has a donor fluorophore and SEQ ID NO:4, which has an acceptor fluorophore.

Abstract: A medication dispensing compliance device with interconnectivity to common vital sign monitoring devices such as blood pressure cuffs, glucometers, weight scales, pulse oximeters, heart rate monitors, body temperature, respirometers and other vital sign monitoring apparatus and a system for the aggregation of medication management and clinical vital signs to monitor patient compliance and efficacy of prescribed medications.

Abstract: A computer-assisted method for assisting a health advocate professional in counseling employees of a plan sponsor comprising receiving health records of employees of a plan sponsor, analyzing data in the records, displaying the analyzed data for any selected employee in dashboard format, calculating any health improvement options for the selected employee, and displaying the health improvement options in the form of questions to be asked by a health advocate professional viewing the displayed dashboard, preferably arranged in categories under spotlight buttons, and a computer system adapted to carry out the method. The method and system can also provide in some embodiments summary medical benefits usage information to plan sponsors, including costs, health improvement options, return on investment.